Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  O6-benzylguanine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-22 of 22 for your search:
Start Over
S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000068656, S0001, U10CA032102, SWOG-S0001, NCT00017147
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-2012-02927, CASE 3405-CC304, 7080, R21CA115057, U01CA062502, P30CA043703, CASE-CWRU-3405, NCT00961220
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CWRU1A96, U01CA062502, P30CA043703, NCI-T97-0021, T97-0021, NCT00004072
O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 10227, UCCRC-10227, UCCRC-T99-0088, NCI-T99-0088, NCT00005066
Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 0059, DUMC-0059-00-1, DUMC-T98-0059, NCI-T98-0059, CDR0000067688, T98-0059, NCT00005081
O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02340, UCCRC-10325, CWRU-1699, NCI-T99-0111, CDR0000067943, T99-0111, NCT00005961
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CWRU1298, U01CA063200, P30CA043703, NCI-89, 89, NCT00005981
Gliadel Wafer and O6-Benzylguanine in Treating Patients With Recurrent Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: Pro00004127, DUMC-5515-06-1R2, DUMC-5515-04-1R0, GP-DUMC-5515-06-1R2, CDR0000483768, NCT00362921
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000529875, NCI-07-C-0052, AOI-NCI-07-C-0052, NCT00436436
O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-03050, PBTC-015, NCI-06-C-0089, NCI-P6692, CDR0000455561, NCT00275002
Phase I Study of O6-Benzylguanine plus Carmustine for Advanced Melanoma, Breast Cancer, Colorectal Cancer, Lymphoma, Gliomas, and Other Adult Solid Tumors (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-7341, NCI-T94-0082C, T94-0082
O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CWRU1994, U01CA062502, CWRU-ICC-1994, NCI-T94-0022D, T94-0022, NCT00002604
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065479, NABTC-9702, NCI-T96-0103, NCT00002971
Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000066327, DUMC-1094-99-6R5, DUMC-929-97-6R3, DUMC-980-98-6R4, NCI-T94-0080, T94-0080, NCT00003348
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-01842, POG-9870, CDR0000066891, P9870, NCT00003765
O6-benzylguanine Followed by Surgery in Treating Patients With Solid Tumors That Can Be Removed During Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 9523, UCCRC-9523, NCI-T98-0038, T98-0038, NCT00003766
Phase I Study of Polifeprosan 20 With Carmustine Implants (Gliadel Wafers) and O6-Benzylguanine in Patients With Recurrent Malignant Glioma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTT-9803, JHOC-NABTT-9803, NCT00004892
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: CDR0000067880, NCI-00-C-0105I, NCI-237, 237, NCT00020150
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 1388, DUMC-1388-02-8R2, DUMC-1388-00-8, NCI-490, DUMC-1388-01-8R1, CDR0000068301, 490, NCT00006474
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-03174, CDR653709, PBTC-005, U01CA081457, NCT00052780
O6-Benzylguanine and Temozolomide in Combination With Genetically Modified Peripheral Blood Stem Cells in Newly Diagnosed Glioblastoma Multiforme
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: CASE6307, NCI-2011-02566, 8274, U01CA062502, CWRU-CASE-6307, NCT01269424
Start Over